Alvotech and Oaktree Acquisition Corp. II Merger Agreement
Related documents
Newsroom
Company news
Business
18 January 2022
Alvotech Upsizes Oversubscribed PIPE Transaction to Approximately $175 Million
Business
10 January 2022
JAMP and Alvotech Announce Canadian Approval of SIMLANDI™, a High-Concentration Biosimilar to Humira®, Providing Access to Previously Unavailable Versions in Canada
Business
16 December 2021
AVT02 Approved for Use in European Union
Business
07 December 2021
Alvotech and Oaktree Acquisition Corp. II Announce Merger Agreement to Create a Leading Publicly-Traded Global Biopharmaceutical Company
Business
08 October 2021
Alvotech beats back Abbvie's trade secrets lawsuit
Business
20 September 2021
Alvotech Provides Update on FDA Action Regarding AVT02, Proposed High-Concentration Biosimilar to Humira® (adalimumab)
Business
17 September 2021
Alvotech Welcomes Positive CHMP Opinion for AVT02, a Proposed Biosimilar to Humira®
Business
13 September 2021
The Future of Innovation. Alvotech and the University of Iceland hosted a conference on how academia and industry can create value together
Business
10 September 2021